MARKET

ETNB

ETNB

89Bio, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.200
+0.030
+0.72%
Pre Market: 4.050 -0.15 -3.57% 08:14 08/11 EDT
OPEN
4.240
PREV CLOSE
4.170
HIGH
4.270
LOW
4.020
VOLUME
5.00K
TURNOVER
--
52 WEEK HIGH
21.47
52 WEEK LOW
2.000
MARKET CAP
163.91M
P/E (TTM)
-0.8405
1D
5D
1M
3M
1Y
5Y
Expert Ratings for 89bio
Analysts have provided the following ratings for 89bio (NASDAQ:ETNB) within the last quarter:
Benzinga · 07/28 20:27
--HC Wainwright Adjusts Price Target on 89bio to $26 From $29, Reiterates Buy Rating
--HC Wainwright Adjusts Price Target on 89bio to $26 From $29, Reiterates Buy Rating
MT Newswires · 07/28 05:06
This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations
In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG). SVB Leerink views these results as 'strong' and says they provide a clear win for the compa...
Benzinga · 07/11 18:15
SVB Leerink slashes PT on 89bio
SVB Leerink has lowered its price target on 89bio (NASDAQ:ETNB) from $50 to ...
Seekingalpha · 07/11 15:55
SVB Securities Adjusts 89bio's Price Target to $29 from $50, Keeps Outperform Rating
MT Newswires · 07/11 10:59
89Bio rallies on Deep Track Capital disclosing 10% stake
89Bio (NASDAQ:ETNB) <a href="https://seekingalpha.com/filing/6567405?source=...
Seekingalpha · 07/07 14:41
Longeveron, Adverum top healthcare gainers; while DiaMedica, CytomX lead losers' pack
Gainers: Longeveron (LGVN) +16%. Adverum Biotechnologies (<a href="https...
Seekingalpha · 07/07 14:00
GOGL, PRTY and ANVS are among pre market gainers
Target Hospitality (TH) +22%<a href="https://seekingalpha.com/pr/18857399-target-hospitality-announc...
Seekingalpha · 07/07 12:33
More
No Data
Learn about the latest financial forecast of ETNB. Analyze the recent business situations of 89Bio, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

57.14%Strong Buy
42.86%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ETNB stock price target is 24.29 with a high estimate of 35.00 and a low estimate of 14.00.
High35.00
Average24.29
Low14.00
Current 4.200
EPS
Actual
Estimate
-1.13-0.85-0.56-0.28
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 76
Institutional Holdings: 18.07M
% Owned: 88.80%
Shares Outstanding: 39.03M
TypeInstitutionsShares
Increased
24
1.61M
New
23
712.99K
Decreased
18
1.06M
Sold Out
4
1.50M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Steven Altschuler
Chief Executive Officer/Director
Rohan Palekar
Chief Financial Officer
Ryan Martins
Chief Operating Officer
Ram Waisbourd
Chief Technology Officer
Quoc Le-Nguyen
Other
Hank Mansbach
Independent Director
Edward Atkinson
Independent Director
Derek Di Rocco
Independent Director
Gregory Grunberg
Independent Director
Michael Hayden
Independent Director
Kathleen Laporte
Independent Director
Lota Zoth
No Data
No Data
About ETNB
89Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The Company's lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). NASH is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma (HCC) and death. The Company is evaluating the potential opportunity for pegozafermin in these fibrosis stage F4 patients. SHTG is a condition identified by severely elevated levels of triglycerides. The Company has initiated its Phase II trial (ENTRIGUE) in SHTG patients.

Webull offers kinds of 89bio Inc stock information, including NASDAQ:ETNB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ETNB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ETNB stock methods without spending real money on the virtual paper trading platform.